Calithera Biosciences Inc. (CALA) Hits New 52-Week Low at $2.89
Calithera Biosciences Inc. (NASDAQ:CALA) hit a new 52-week low on Tuesday . The company traded as low as $2.89 and last traded at $3.00, with a volume of 1,294,324 shares trading hands. The stock had previously closed at $3.49.
A number of brokerages have recently weighed in on CALA. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $10.48.
The stock’s 50-day moving average price is $4.32 and its 200 day moving average price is $5.19. The firm’s market capitalization is $56.68 million.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.05. Equities analysts anticipate that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.